Denver Anchor Resigns To Focus On Bladder Cancer Treatment
Chris Parente leaves his position at KWGN to complete his ongoing medical care by February 2027.
Updated on Oct. 15, 2026 in Cancer
Denver television anchor Chris Parente has resigned from his position at KWGN after seven years to focus on ongoing treatment for bladder cancer. Parente, who hosted the morning program Daybreak, concluded his tenure on October 12, 2026.
Why it matters
Managing cancer treatment alongside a high-pressure career can be physically demanding, with side effects like fatigue and pain often necessitating significant lifestyle adjustments. Parente's public transition underscores the difficulty of maintaining demanding broadcast schedules during intensive medical care.
Parente's treatment path included both bacillus Calmette-Guérin (BCG) immunotherapy and intravesical chemotherapy. His recovery process is anticipated to continue until February 2027.
The players
Chris Parente
A veteran Denver television anchor and seven-time Emmy Award winner who hosted the program Daybreak.
KWGN
A Denver-based television station that broadcasts daily news and information programs.
The details
Bacillus Calmette-Guérin is a common immunotherapy used to treat early-stage bladder cancer by stimulating the body's immune system to attack cancer cells within the lining of the bladder. Intravesical chemotherapy involves delivering medication directly into the bladder through a catheter to minimize systemic side effects while targeting the tumor. These combined approaches are standard protocols for managing localized bladder malignancies, though they require significant recovery time.
Timeline
October 11, 2025: Parente first noticed symptoms of his illness.
October 16, 2025: A CT scan revealed a tumor in Parente's bladder.
October 12, 2026: Parente delivered his final broadcast for KWGN.
February 2027: Expected completion of Parente's current medical treatment regimen.
Health Landscape
Parente's treatment regimen of BCG immunotherapy and localized chemotherapy follows the standard care protocols established by organizations like the National Cancer Institute for managing bladder cancer. This approach highlights the intensive nature of specialized bladder cancer care, which often requires a lengthy schedule of office-based procedures.
Recognizing early symptoms like unexpected bladder pain or changes in urinary health is critical, as these symptoms prompted Parente's initial screening. Anyone experiencing persistent changes in urinary function should consult a physician to discuss appropriate diagnostic imaging, such as a CT scan.
The takeaway
Bladder cancer treatment often involves a combination of targeted immunotherapy and chemotherapy that can span many months. If you notice unusual changes in urinary habits, bring them to your doctor's attention early for a professional evaluation.
What happens next
Parente's current medical treatment regimen is expected to conclude in February 2027.
Further reading
For more information on navigating treatment and symptoms, visit our Cancer section.
Source note: This article includes information reported by NewscastStudio.
